Detalhe da pesquisa
1.
Pharmacokinetics, mass balance, metabolism, and excretion of the liver-targeted acetyl-CoA carboxylase inhibitor PF-05221304 (clesacostat) in humans.
Xenobiotica
; 52(3): 240-253, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-35382680
2.
Metabolites in safety testing assessment in early clinical development: a case study with a glucokinase activator.
Drug Metab Dispos
; 42(11): 1926-39, 2014 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-25142735
3.
Inhibition of Diacylglycerol Acyltransferase 2 Versus Diacylglycerol Acyltransferase 1: Potential Therapeutic Implications of Pharmacology.
Clin Ther
; 45(1): 55-70, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36690550
4.
Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) study.
BMJ Open
; 12(3): e056159, 2022 03 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35354614
5.
ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials.
Nat Med
; 27(10): 1836-1848, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34635855
6.
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Liver-Targeting Acetyl-CoA Carboxylase Inhibitor (PF-05221304): A Three-Part Randomized Phase 1 Study.
Clin Pharmacol Drug Dev
; 9(4): 514-526, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32065514
7.
Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor.
Clin Pharmacokinet
; 59(8): 949-965, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32337660
8.
Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis.
Sci Transl Med
; 11(520)2019 11 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-31776293
9.
Glycemic Effect and Safety of a Systemic, Partial Glucokinase Activator, PF-04937319, in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin-A Randomized, Crossover, Active-Controlled Study.
Clin Pharmacol Drug Dev
; 5(6): 517-527, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27870481
10.
Influence of i.v. haloperidol on ventricular repolarization and monophasic action potential duration in anesthetized dogs.
Chest
; 125(5): 1821-9, 2004 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-15136396